2-mercaptoethanesulfonic acid
As of the edition of 20 October 2026, 2-mercaptoethanesulfonic acid is a small molecule: marketed, first approved in 1980 (ES).
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Marketed; latest approval 2008
- Kind
- Small molecule
- Brand name
- Mesnex
- First approved
- 1 March 1980 (ES)
- Approvals on record
- 9 in 5 regions
- Holder of the most recent approval
- Baxter Healthcare; 4 holders in all
- Withdrawn from market
- 1 January 1991 (in some regions)
- Registered trials
- 175, 41 stopped early
- Disease areas
- Cancer; Blood and lymph; Immune system; Skin and connective tissue; Nervous system; Inherited and neonatal
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 18 | 6 | 4 | 6 |
| Phase 1 | 37 | 12 | 12 | 11 |
| Phase 2 | 100 | 53 | 25 | 19 |
| Phase 3 | 18 | 10 | 1 | 5 |
| Phase 4 | 2 | 0 | 0 | 0 |
| All trials | 175 |
Who has held its approvals
| Company | Role | Years |
|---|---|---|
| Baxter Healthcare | Applicant and Acquired holder | 1999 to now |
| Bristol Myers Squibb | Later holder | 2002 to now |